Detailed understanding of molecular mechanisms controlling adipogenesis is of great importance to identify new targets for treating obesity. Emerging evidence suggests that long noncoding RNAs (lncRNAs) may play a pivotal role in adipogenesis. Here, we have identified a novel lncRNA, Plnc1, which is transcribed from a position ∼25,000 bp upstream of the peroxisome proliferator-activated receptor g2 (PPAR-g2) gene. Plnc1 is abundantly expressed in adipose tissue, and obese mice have higher Plnc1 expression in adipose tissue than nonobese mice. Plnc1 was induced in established adipogenic lines ST2, 3T3-L1, and C3H10T1/2 as well as in bone marrow stromal cells (BMSCs) after adipogenic treatment. Plnc1 knockdown blocked differentiation of ST2 cells and BMSCs into mature adipocytes, along with the reduction of PPAR-g, CCAAT/enhancer binding protein-a, and adipocyte protein 2. Conversely, overexpression of Plnc1 promoted ST2 cells and BMSCs to fully differentiate. Mechanism studies revealed that Plnc1 could reduce the methylation level of CpG region in the PPAR-g2 promoter and enhance the transcriptional activity of the promoter and thereby increase PPAR-g2 transcription. Our study suggests that Plnc1 promotes adipogenic differentiation through controlling the key adipogenic transcription factor PPAR-g and highlights the potential of Plnc1 as a target for new therapies to control metabolic disorders like obesity
As a global epidemic, the prevalence of obesity has increased at an alarming rate over the past several decades. In individuals with obesity, the lipolytic activity and adipokine function of fat cells are altered, which results in the development of numerous metabolic complications, such as type 2 diabetes mellitus, hyperlipidemia, arteriosclerosis, and cardiovascular disease (1) . Enhanced caloric intake and reduced exercise are predominant factors that drive the development of obesity. Hyperplasia (generating new adipocytes) and hypertrophy (increasing lipid content of adipocytes) are major contributors of obesity (2, 3) . Indeed, the two processes are largely dependent on the regulation of adipogenic differentiation (4) . Therefore, the tight control of adipogenesis is critical in regulating whole-body energy homeostasis, and the identification of the molecular mechanisms controlling adipogenic differentiation is essential for the expoloration of new strategies to treat obesity.
Adipogenic differentiation is a tightly controlled process, during which mesenchymal stem cells develop into mature adipocytes, which requires sequential activation of multiple transcription factors (5) . A variety of cellular model systems are used to study the molecular pathways of adipogenesis, including mesenchyme-derived precursor cell lines such as ST2 and C3H10T1/2 cells, and established fibroblast like preadipocytes such as 3T3-L1 cells (3, 6) . It is well established that 2 pivotal players exist during the entire terminal adipogenic differentiation process: 1) the CCAAT/enhancer binding protein (C/EBP)a, and 2) peroxisome proliferator-activated receptor g (PPAR-g) (5) . Ectopic expression of C/EBPa in a variety of mouse fibroblastic cells could induce adipogenesis (7) , and C/EBPa 2/2 mice were almost completely devoid of white adipose tissue (WAT) (8) . Murine PPAR-g is expressed as 2 isoforms, named PPAR-g1 and PPAR-g2, which are generated by alternative promoter usage of the same gene. PPAR-g2 mRNA encodes an additional 30 aa N-terminal to the first ATG codon of PPAR-g1 mRNA (9) . The key role of PPAR-g in adipogenesis is supported by overwhelming evidence from both in vitro and in vivo studies. PPAR-g is both necessary and sufficient for adipogenic differentiation, and none of the other known factors could promote adipogenesis in the absence of PPAR-g (10) . Whereas PPAR-g2 expression is restricted to adipose tissue, PPAR-g1 is expressed in many tissues and can compensate for the adipogenic function of PPAR-g2 (6, 11) . Upon adipogenic induction, PPAR-g coordinates with C/EBPa to trigger adipogenic marker gene expression, such as adipocyte protein 2 (aP2), fatty acid synthase, and lipoprotein lipase (12) .
Only ,2% of the mammalian genome carries proteincoding potential, yet .90% is transcribed at some point during development to produce a large transcriptome of long noncoding RNAs (lncRNAs, defined as RNAs .200 nt in length) (13, 14) . The fascinating story of lncRNAs debuted in the phenomena of genomic imprinting. As one of the first lncRNAs to be discovered in mammals, the Xinactive-specific transcript is transcribed only from the inactive X chromosome and regulates dosage compensation by promoting X-chromosome inactivation (15, 16) . The identification of lncRNAs provides a new perspective on gene regulation in numerous biologic functions and cellular processes, including development, proliferation, apoptosis, survival, and differentiation (17) . Recent evidence suggests that lncRNAs play important roles in the development and function of WAT and brown adipose tissue (18, 19) . Using whole-transcriptome RNA sequencing, a cluster of lncRNAs that exhibited differential expression levels during adipogenesis was identified, several of which appeared to be required for adipocyte differentiation. lncRNA steroid receptor RNA activator (SRA) could bind to and coactivate PPAR-g to promote adipocyte differentiation, and SRA gene knockout mice were resistant to developing obesity induced by a high-fat diet (20, 21) . PU.1 antisense (PU.1 AS) lncRNA was capable of binding to PU.1 mRNA to prevent its translation and thereafter promoted adipogenesis (22) . Sun et al. (23) identified more than 175 differentially regulated lncRNAs with massive parallel sequencing of polyadenylation-selected RNAs during adipogenesis in both WAT and brown adipose tissue. In adipocytes, the promoters of 57 of these 175 genes were bound by PPAR-g and C/EBPa, and silencing of 10 selected lncRNAs led to strong attenuation of lipid accumulation. In spite of these findings, the role and regulatory mechanisms of lncRNAs in adipogenesis are far from being understood.
In the current report, we have identified a novel lncRNA Plnc1, which was previously reported as a transcript by several genome exploration research groups (24, 25) . However, the function of Plnc1 is unknown. In our preliminary microarray analysis, we found that Plnc1 expression increased during adipogenic differentiation of bone marrow stromal cells (BMSCs). We therefore hypothesized that Plnc1 might play a role in adipocyte differentiation. This study was designed to test this hypothesis and to determine the possible molecular mechanisms involved in Plnc1 regulation of adipocyte differentiation.
MATERIALS AND METHODS

Ethics statement, mice
All animal experiments and procedures were approved by the Animal Ethical and Experimental Committee of Tianjin Medical University. Eight-week-old male C57BL/6J mice, ob/ob, and KK/ Upj-Ay/J (KKAy) fat mice were purchased from HFK Bioscience (Beijing, China). The mice were euthanized after deep anesthesia with ether. The murine tissues were collected and snap frozen in liquid nitrogen.
Cells culture
3T3-L1, C3H10T1/2, and HEK-293T cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS). ST2 cells were cultured in a-MEM supplemented with 10% FBS. BMSCs were isolated from femurs and tibiae of 6-wk-old C57BL/ 6J mice and cultured in a-MEM supplemented with 10% FBS in 10-cm dishes as previously described (26) . All cells were maintained in a humidified incubator containing 5% CO 2 at 37°C.
For adipogenic differentiation, 90% confluent cells were cultured in adipocyte-inducing medium (a-MEM containing 10% FBS, 0.5 mM dexamethasone, 0.25 mM methylisobutylxanthine, 5 mg/ml of insulin, and 50 mM indomethacin) for 72 h, followed by treatment for an additional 48 h with 5 mg/ml insulin alone.
Reagents eGFP tag antibody was purchased from Proteintech (Wuhan, China). Anti-b-actin was purchased from MilliporeSigma (Burlington, MA, USA). Anti-C/EBPa, anti-PPARg, and anti-aP2 were purchased from Cell Signaling Technology (Danvers, MA, USA). Lipofectamine RNAiMax was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Attractene Transfection Reagent was purchased from Qiagen (Hilden, Germany).
Cell transfection
Oligonucleotide and plasmid transfections were performed with Lipofectamine RNAiMax or Attractene Transfection Reagent according to the manufacturer's protocol. Briefly, cells were seeded in plates the day before transfection to ensure a suitable cell confluent on the day of transfection. For oligonucleotides, 50 nM of short interfering RNA (siRNA) or its negative control RNA (si-NC) (GenePharma, Shanghai, China) was used. For plasmid DNA, 0.4 mg DNA/well was used in 24-well plates, or 0.8 mg DNA/well was used in 12-well plates.
Quantitative RT-PCR
Total RNA was extracted from cells using a total RNA isolation kit (Omega Bio-Tek, Norcross, GA, USA), and 0.5 mg RNA of each sample was reverse-transcribed to cDNA with a Reverse Transcription Kit (Thermo Fisher Scientific, Shanghai, China). Quantitative PCR (qPCR) analyses for the mRNA expression were performed as previously described (27) by using TransStart Green qPCR SuperMix (TransGen Biotech, Beijing, China) on the Light Cycler 96 Real-Time PCR System (Roche Diagnostics, Mannheim, Germany). The relative expression levels of the target genes were calculated using the comparative threshold cycle method (28) . The levels of NONO (29) and b-actin were used as internal controls for lncRNA and mRNA, respectively. The primers testing the mRNA levels of SRA and PU.1 AS were used as previously described (20, 22) . The other primer sequences used in the study are listed in Supplemental Table 1 .
Rapid amplification of cDNA ends assays
Total RNA extracted from ST2 cells was subjected to rapid amplification of cDNA ends (RACE) PCR with a (Switching Mechanism at 5' End of RNA Template (SMARTer) RACE 59/39 Kit (Takara Bio, Mountain View, CA, USA) according to the manufacturer's specifications. The appropriate gene-specific primers are listed in Supplemental Table 1 .
RNA interference
Double-stranded siRNA oligonucleotides targeting SRA (59-GACCACUGCAAGAUCACUUGUTT-39) and PU.1 AS (59-AAUCGUAAGUAACCAAGUCAUTT-39) were used as previously described (20, 22) . Two different siRNA constructs targeting Plnc1 (GenBank accession number, AK085865, chr6: 115395605-115396870; National Center for Biotechnology Information, Bethesda, MD, USA; https://www.ncbi.nlm.nih.gov/ genbank/) mRNA and si-NC were designed using the Block-It RNAi Designer tool (Thermo Fisher Scientific; https://thermofisher. com/rnaiexpress/). The sense oligonucleotides were siRNA-1 59-CCACAAGAAGCCACCUCAATT-39, siRNA-2 59-GGGAAA-GUUAUGGCUGCAATT-39, and si-NC 59-UUCUCCGAACG-UGUCACGUTT-39.
Construction of plasmids
eGFP was PCR amplified and cloned into pcDNA3.1 (+) vector at the KpnI/XbaI sites. The resultant construct is named pcDNA3.1-eGFP. To assess the coding potential of Plnc1, coding potential calculator (CPC, http://cpc.cbi.pku.edu.cn/) and coding potential assessment tool (CPAT, http://lilab.research.bcm.edu/cpat/) were used. Besides, full-length PCR fragment of Plnc1 fused with N-terminal start codon ATG was inserted into the eukaryotic expression vector pcDNA3.1-eGFP without or with 1 or 2 thymidines added between the sequences of Plnc1 and eGFP. These resulted in 3 separate constructs and would help to exclude the possibility that the failure of the construct to express eGFP was due to frame-shift of the eGFP coding. To make the Plnc1-eGFP fusion constructs, ATG-Plnc1 fragment and pcDNA3.1-eGFP were PCR amplified, and then the resulting products were in-fusion cloned by using an In-Fusion HD Cloning Kit (Takara Bio). The used primers are listed in Supplemental Table 1 . Construct of C/EBPa-eGFP was made as well and used as a positive control. Next, the sequence of the 5'flanking region of Plnc1 was analyzed with online searching tools of Transcription Factor Binding Sites TFBIND (http://tfbind.hgc.jp/) and JASPAR (http://jaspar.genereg.net/). The 1.6 kb mouse PPAR-g1 promoter was inserted into the Gaussia Luciferase (GLUC) reporter plasmid, which contains the GLUC and Secreted Alkaline Phosphatase reporter gene (Gene Copoeia, Guangzhou, China). The promoterless vector pGL4.14 (luc2/Hygro; Promega, Madison, WI, USA) was used to make the promoter construct of Plnc1 and PPAR-g2. A 2.0-kb wild-type mouse PPAR-g2 promoter fragment and a 1.2-kb 59-flanking sequence of Plnc1 were PCR amplified and then inserted into the vector at XhoI/EcoRV or XhoI/HindIII sites. The sequences of the primers are listed in Supplemental Table 1 .
Lentivirus packaging and transduction
To knockdown Plnc1 expression, the short hairpin RNA (shRNA) coding construct was made by inserting the annealed oligo pair into the pLVX-shRNA2 vector (Clontech Laboratories, Mountain View, CA, USA) at the BamHI/EcoRI sites.
For overexpression studies, the Plnc1 and SRA sequences were PCR amplified and separately cloned into pcDNA3.1 (+) vector at the BamHI/EcoRI sites or the HindIII/EcoRI sites. The Plnc1 fragment was also cloned into lentiviral vector pCDH-CMV-MCS-EF1-copGFP (System Bioscience, Mountain View, CA, USA) at the EcoRI/BamHI sites.
The lentiviruses were packaged by cotransfecting 293T cells with the previously mentioned lentiviral transfer plasmids, packaging (GAG/Pol and REV) plasmids, and envelope (VSV-G) plasmid using the lentiviral packaging system (Jiman Biotech, Shanghai, China). The medium was changed 18 h after transfection, and the cells were cultured for additional 2 d. The viruses were harvested, concentrated, and titered. The viruses were used at a multiplicity of infection of 10 to infect BMSCs.
The sequences of primers and the complementary oligonucleotides used are shown in Supplemental Table 1 .
Western blotting
Treated cells were lysed by RIPA Lysis Buffer (Beyotime, Shanghai, China), and the immunoblotting was performed as previously described (30) . Briefly, the protein was separated in 12% SDS denatured polyacrylamide gel and then transferred onto a PVDF membrane. The membranes were blocked with 5% skim milk and were incubated with appropriate antibodies at 4°C overnight. Membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibodies (1:3000; TransGen Biotech). The protein of interest was visualized using Immobilon Western Chemiluminescent HRP Substrate (Thermo Fisher Scientific).
Oil Red O staining
Differentiated adipocytes were fixed in 4% paraformaldehyde for 10 min, washed twice with deionized water, and then stained with 60% saturated Oil Red O for 5 min. For Oil Red O quantification, isopropanol was added to each well. Light absorbance was measured at 520 nm.
Cell nucleus/cytoplasm fractionation
For cytoplasmic fraction, cells were washed with cold PBS and lysed in 0.1% NP40 (dissolved in PBS) with protease inhibitor cocktail and 10 mM Ribonucleoside Vanadyl Complex (Thermo Fisher Scientific). After short centrifugation, the supernatant was collected as the cytoplasmic fraction, and the remainder was washed and considered as nuclear pellets.
DNA methylation analysis
Genomic DNA from treated cells was prepared using the E.Z.N. A. Tissue DNA Kit (Omega Bio-Tek). Bisulfite treatment of extracted genomic DNA was performed with an EpiTect Fast DNA Bisulfite Kit (Qiagen). The methylation-specific PCR (MSP) consisted of 40 cycles (95°C for 30 s, 50°C for 30 s, and 72°C for 20 s) after an initial denaturing step (95°C for 5 min). The primers were designed based on the previously reported 2437 and 2247 bp CpG sites on the PPAR-g2 promoter (31) (Supplemental Table 1 ). For quantitative methylation assay, a sensitive 2-step qPCR method was applied as previously described (32). In brief, the bisulfite-converted genomic DNA containing the CpG regions of interest was amplified with nested PCR using the outer methylation-independent PCR (MIP) primers: outer MIP-F, 59-AGGGAGGGTTTTAATTTTTTTATT-39 and outer MIP-R, 59-AAAAAATCTCCCAAAATTTCAC-39. The resultant product was used as an input template of qPCR with MSP primers (MS-qPCR). The first PCR product was also used as template in a qPCR with the inner MIP primers (inner MIP-qPCR): inner MIP-F, 59-ATTTGTGTGGGTAATAAAATTTAAAATAAG-39 and inner MIP-R, 59-AATCAAAACACCAATTTTCAAA-39. The results of the MS-qPCR were normalized to the results of the inner MIP-qPCR. To evaluate the methylation status of the reporter constructs, bisulfate-sequencing PCR was performed. Briefly, total DNA from the reporter construct-transfected cells was prepared and bisulfite converted. A fragment that spans from the upstream of the 2437 bp CpG site in the PPAR-g2 promoter to the downstream of start codon of luciferase in the construct was amplified by the methylation-independent primers: inner MIP-F and bisulfate-sequencing PCR-R, 59-CCATAATAACTTTACCAACAATACC-39. The product was cloned into the ZT4-Blunt vector (Zoman Biotechnology, Beijing, China), and 10 clones from each group were sequenced.
Luciferase reporter assay
To obtain nonmethylated and methylated plasmids, the reporter constructs were transformed into a dam 2 /dcm 2 Escherichia coli strain (Trans110; TransGen Biotech). The plasmids were isolated and incubated with 4 U/mg SssI methylase (New England Biolabs, Beijing, China) in the presence of 640 mM S-adenosyl methionine at 37°C for 4 h.
3T3-L1 cells were cotransfected with the promoter construct and Plnc1 siRNA or expression plasmid for 36 h. The Renilla luciferase reporter plasmid pRL-SV40 was included in the cotransfection mixture to monitor the transfection efficiency of firefly luciferase reporter. Luciferase assay was done using a Dual-Luciferase Reporter Assay Kit (Promega). The GLUC and secreted alkaline phosphatase activity assay was performed with a Secrete-Pair Dual Luminescence Assay Kit (Gene Copoeia).
Statistical analysis
The results are expressed as mean 6 SD. A 2-tailed Student's t test was applied to analyze the differences between 2 groups, and a 1way ANOVA, followed by a Tukey's test were used to analyze the differences among multiple groups. Statistical analysis was performed with SPSS software (v.17) (IBM, Armonk, New York, US; https://www.ibm.com/analytics/spss-statistics-software). A value of P , 0.05 indicated statistical significance.
RESULTS
Plnc1 was identified as a long noncoding RNA
To identify the lncRNAs involved in the adipogenic differentiation of mouse BMSCs, microarray analysis was done to analyze the mRNA and lncRNA expression profiles in the cells subjected to adipogenic treatment for 3 d. A fold change of the C t value of .2 was regarded as significantly different. We focused on an uncharacterized RNA transcript (Fig. 1A) , Plnc1, which was transcribed from the intron between PPAR-g1 exon A2 and PPAR-g2 exon B1 (Fig. 1B) . The results from microarray analysis indicated that Plnc1 and PPAR-g2 synergistically increased on d 3 compared with undifferentiated BMSCs (Fig. 1C) . The 59 and 39 rapid amplification of cDNA ends analysis revealed that the Plnc1 transcript was polyadenylated and transcribed from a single exon of ;1128 bp ( Fig. 1D, E) . According to transcription potential measurement with CPC (33) and CPAT (34) , Plnc1 was predicted as a noncoding RNA with very poor protein-coding potential, similar to the well-known lncRNAs metastasis associated lung adenocarcinoma transcript 1 (MALAT1) and HOX transcript antisense RNA (HOTAIR) ( Table 1) .
Next, we analyzed the sequences of the 59-flanking region of Plnc1 with online and JASPAR, which revealed a TATA-like sequence, a PPAR-a binding site, and several C/EBP binding motifs in the proximal region (Supplemental Fig. 1A) . A 1.2 kb 59-flanking sequence was cloned and transfected into HEK-293 and C3H10T1/2 cells. Luciferase reporter assays revealed the transcriptional activity of this putative promoter. Furthermore, adipogenic treatment of C3H10T1/2 increased the transcriptional activity of the construct (Supplemental Fig. 1B) . These data further suggest that Plnc1 is independently transcribed.
To test if Plnc1 is incapable of coding, we made 3 constructs containing full-length Plnc1, which follows an Nterminal start codon ATG and is fused with a C-terminal eGFP tag in all 3 reading frames (Fig. 1F) . These 3 plasmids were transfected separately for 48 h into HEK-293T cells. Western blotting and fluorescence observation revealed that all 3 constructs failed to express eGFP protein ( Fig. 1F and Supplemental Fig. 1C ). As a control, the C/EBPa-eGFP protein was successfully expressed in cells transfected with pcDNA3.1-C/EBPa-eGFP (Supplemental Fig. 1D ).
Plnc1 was abundantly expressed in adipose tissue and increased in obese mice
The expression levels of Plnc1 were examined in various tissues in 8-wk-old C57BL/6J mice. Plnc1 was highly expressed in epididymal and inguinal fat, moderately expressed in perirenal fat and brain, and relatively low in heart, kidney, liver, lung, skeletal muscle, and interscapular brown fat ( Fig. 2A) . We also compared the expression levels of Plnc1 and adipogenic factors in various adipose tissues of nonobese C57BL/6J mice with those of obese ob/ob and KKAy mice. qRT-PCR analysis indicated that the levels of PPAR-g2, aP2, Fasn, Lpl and Plnc1 were higher in WAT in obese mice than that in nonobese C57BL/6J mice ( Fig. 2B-F ). Furthermore, the expression of Plnc1 in interscapular brown fat did not show significant change in obese mice compared with C57BL/6J mice (Supplemental Fig. 2) . These results suggest that the high expression of Plnc1 is possibly related to obesity.
Plnc1 was up-regulated during adipocyte formation
The expression of Plnc1 was monitored during adipogenesis. Adipogenic differentiation of ST2 cells was confirmed by Oil Red O staining (Fig. 3A, B) . Consistently, qRT-PCR analysis revealed that adipogenic factors PPARg and aP2 were induced after adipogenic treatment. Plnc1 expression was also elevated at all the indicated time points during adipocyte differentiation (Fig. 3C) . The increase of Plnc1 was verified in 3T3-L1, C3H10T1/2, and BMSCs 3 d after adipogenic treatment (Fig. 3D) . These data suggest that Plnc1 may play a regulatory role in adipocyte differentiation.
Silencing of Plnc1 reduced adipocyte differentiation
To identify the role of Plnc1 in adipocyte differentiation, a loss-of-function study was performed using siRNAs. The transfection of 2 siRNAs targeting Plnc1 substantially reduced the expression of Plnc1 (Fig. 4A) . After adipogenic treatment, knockdown of Plnc1 in ST2 cells significantly suppressed adipocyte formation, and Oil Red O quantification revealed decreases of 56 and 37%, respectively, after transfection of Plnc1 siRNAs vs. si-NC (Fig. 4B, C) . qRT-PCR and Western blotting further confirmed that Plnc1 siRNAs decreased expression levels of PPAR-g, C/ EBPa, and aP2 (Fig. 4D, E) . Consistently, Plnc1 siRNA also notably decreased PPAR-g, C/EBPa, and aP2 protein levels during adipocyte differentiation (Fig. 4F ). We further compared the adipogenic effect of Plnc1 with the 2 previously reported lncRNAs PU.1 AS (22) and SRA (20) by using loss-of-function strategy. On the whole, Plnc1 siRNA was as efficient as the siRNAs of PU.1 AS and SRA in blocking adipocyte differentiation (Supplemental Fig. 3A-D) .
We also silenced Plnc1 with 2 separate shRNA lentiviruses in primary BMSCs to verify its function in adipocyte differentiation. qRT-PCR demonstrated the efficacy of shRNA lentiviruses in silencing Plnc1 in BMSCs (Fig. 4G ).
In the presence of adipogenic medium, Plnc1 shRNAs repressed adipocyte formation (Fig. 4H, I) and decreased the mRNA and protein levels of PPAR-g, C/EBPa, and aP2 as compared with the negative control virus (Fig. 4J, K) . These results demonstrate that down-regulation of Plnc1 inhibits adipogenic differentiation.
Overexpression of Plnc1 promoted adipocyte differentiation
A gain-of-function study was conducted to further verify the role of Plnc1 in adipogenic differentiation. qRT-PCR verified the overexpression of Plnc1 in ST2 cells (Fig. 5A) . In the presence of adipogenic medium, Plnc1 overexpression led to a significant increase in the number of differentiated adipocytes vs. vector transfection (28% increase in Oil Red O staining) ( Fig. 5B, C) . Different doses (0.25, 0.5, and 1 mg/ml medium) of Plnc1 transfection showed similar effects on adipocyte differentiation (Supplemental Fig. 4 ). Accordingly, the mRNA and protein levels of PPAR-g, C/EBPa, and aP2 were increased 72 h after adipogenic treatment (Fig. 5D, E) . Furthermore, overepression of Plnc1 showed a effect comparable to SRA in boosting adipocyte differentiation (Supplemental Fig. 3F-H) .
We further investigated the effect of Plnc1 overexpression on adipocyte differentiation using BMSCs. qRT-PCR revealed a 7.3-fold increase of Plnc1 level after infection (Fig. 5F ). In the presence of adipogenic medium, Plnc1 overexpression significantly induced adipocyte differentiation in BMSCs vs. Ctrl LV infection (23% increase in Oil Red O staining) (Fig. 5G, H) . Consistently, mRNA and protein levels of C/EBPa, PPAR-g, and aP2 were increased at 72 h after adipogenic treatment in the cells overexpressing Plnc1 (Fig. 5I, J) . These results demonstrate that overexpression of Plnc1 promotes adipogenic differentiation.
Plnc1 reduced methylation and enhanced transcriptional activity of PPAR-g2 promoter
We next sought to determine the underlying mechanisms by which Plnc1 regulates adipogenic differentiation. The major locus of Plnc1 in cell was investigated. b-Actin and histone H3 proteins were detected exclusively in the cytoplasmic and nuclear fractions, respectively (Fig. 6A) , suggesting that the fractionation of nuclear and cytoplasmic compartments was successful. qRT-PCR analysis indicated that Plnc1 was up-regulated in both cytoplasmic and nulear parts 3 d after adipogenic treatment but with a greater magnitude of increase in the nuclear part ( Fig. 6B ). We also compared the effect of Plnc1 on PPAR-g1 and -g2 expression. Although Plnc1 siRNA decreased PPAR-g1, it affected PPAR-g2 earlier and more potently at the indicated time points (Fig. 6C) . Consistently, Plnc1 silencing inhibited the transcriptional activity of the PPAR-g2 promoter more potently than that of the PPAR-g1 promoter in undifferentiated and differentiated 3T3-L1 cells. Conversely, overexpression of Plnc1 stimulated the PPAR-g2 promoter activity more potently than the PPAR-g1 promoter (Fig. 6D) .
A further in-depth investigation focused on PPAR-g2 promoter by using MSP analysis. Plnc1 knockdown resulted in a higher methylation level of the PPAR-g2 promoter at the 2437 and 2247 sites, whereas Plnc1 overexpression led to a lower methylation level of the PPAR-g2 promoter (Fig. 6E) . A sensitive 2-step MS-qPCR analysis was applied ( Fig. 6F ), which consistently showed increased methylation when silencing and decreased methylation when overexpressing Plnc1 in the cells (Fig. 6G) .
We investigated the effect of methylation on promoter activity. The data revealed that the nonmethylated PPAR-g2 promoter had higher transcriptional activity than the methylated promoter in cells cultured with basal medium and that the activity was even higher in adipogenic medium. Plnc1 overexpression further increased PPAR-g2 promoter activity in nonmethylated and methylated status (Fig. 6H ). Further exploration revealed that Plnc1 overexpression reduced DNA methylation levels on the methylated promoter construct of PPAR-g2 (Supplemental Fig. 5 ). Taken together, these data suggest that Plnc1 enhances the promoter activity of PPAR-g2 through attenuating the methylation status of the promoter, thereby increasing PPAR-g2 transcripts.
DISCUSSION
Obesity has emerged as an epidemic and has become an unprecedented public health challenge. Recent studies have confirmed the relationship between obesity and dysregulation of adipogenesis (35) . Therefore, the precise molecular mechanisms modulating adipogenesis should be fully understood to help provide new therapeutic strategies to combat obesity.
lncRNAs are defined as a class of RNA transcripts longer than 200 nt. They are often polyadenylated and are devoid of evident open reading frames (36) . lncRNAs have crucial roles in gene expression control during cell development and differentiation (37) . Emerging evidence strongly indicates that lncRNAs are involved in the regulation of adipogenesis, WAT development and function, and obesity (38) .
In this study, we have identified an lncRNA with adipogenic potential, Plnc1 which was initially reported as a transcript by genome exploration research groups (24, 25) . It is regarded as an independent noncoding RNA based on the following evidence: 1) transcription potential measurements using coding potential calculator and coding potential assessment tool suggest a very poor protein-coding potential of Plnc1, 2) the proximal 59flanking region of Plnc1 shows transcriptional activity, and 3) fluorescence observation and Western blotting revealed that the constructs containing full-length Plnc1 fused with eGFP failed to express eGFP protein.
The expression levels of Plnc1 were examined in various tissues in 8-wk-old C57BL/6J mice. The result revealed that Plnc1 was highly expressed in fat tissues and was significantly up-regulated in adipose tissues from obese ob/ob and KKAy mice vs. nonobese control mice (Fig. 2) . These data suggest that the high expression of Plnc1 is possibly related to obesity.
Adipogenesis is tightly correlated to obesity. Therefore, we examined the expression of Plnc1 during adipocyte differentiation. The data revealed that Plnc1 was substantially up-regulated during adipocyte differentiation in ST2, 3T3-L1, and C3H10T1/2 cells and in BMSCs (Fig. 3 ). Several lncRNAs have been identified to regulate adipocyte differentiation. For instance, lncRNA adipogenic differentiation induced noncoding RNA binds to PA1 and recruits MLL3/4 histone methyltransferase complexes to increase H3K4me3 and decrease H3K27me3 histone modification at the C/EBPa locus, thereby enhancing the transcriptional activation of C/EBPa to promote adipogenesis (39) . Ectopic overexpression of lncRNA HOTAIR enhances the differentiation of abdominal preadipocytes by inducing expression of PPAR-g and lipoprotein lipase (40) . In the current study, we tried to determine whether Plnc1 regulates adipocyte differentiation by using loss-and gain-of-function studies. The data showed that Plnc1 silencing in ST2 cells and BMSCs dramatically blocked adipogenic differentiation, as evidenced by reduced differentiated adipocytes and decreased expression of adipogenic factors PPAR-g, C/EBPa, and aP2 (Fig. 4) . Conversely, overexpression of Plnc1 stimulated the formation of adipocytes (Fig. 5 ). Further investigation demonstrated that Plnc1 is as effient as the 2 previously reported lncRNAs PU.1 AS and SRA in boosting adipocyte differentiation (Supplemental Fig. 2) . We next explored the molecular mechanism underlying the function Plnc1 in vitro. Bioinformatics analysis indicated that Plnc1 is located in the intron between PPAR-g1 exon A2 and PPAR-g2 exon B1 and on a position ;25 kb upstream of PPAR-g2 exon B1 (Fig. 1B) . Recent reports have suggested that lncRNAs arising from promoter and enhancer regions could have significant roles in controlling the expression of downstream genes (41) , and several intronic sense lncRNAs could transcriptionally regulate their neighboring protein-coding genes in cis (42) . In our study, knockdown or overexpression of Plnc1 had a strong effect on the expression of its nearby coding gene PPAR-g. We also found that Plnc1 was largely up-regulated in the nuclear compartment as compared with cytoplasmic fraction at d 3 after adipogenic treatment. These data suggest that Plnc1 may exert its function during adipocyte differentiation through regulating PPAR-g. In support of this hypothesis, we further demonstrated that Plnc1 positively regulated the expression of PPAR-g2 earlier and more potently than that of PPAR-g1. The up-regulation was due to the stimulation of PPAR-g2 promoter activity in response to Plnc1.
In this study, we asked how Plnc1 affects the transcriptional activity of PPAR-g2. Because of the overwhelming role of PPAR-g2 in adipogenesis, many studies tend to focus on PPAR-g2 when illustrating mechanisms controlling adipogenesis. Several lncRNAs have been found to regulate adipogenesis through modulating the expression of PPAR-g2. Lnc-U90926 suppressed 3T3-L1 adipocyte differentiation through inhibiting the transactivation of the PPAR-g2 promoter (43) . lncRNA NEAT1 works with SRp40 to regulate PPAR-g2 splicing during adipogenesis in 3T3-L1 cells (44) . It is known that the methylation of DNA in 59 promoters usually suppresses gene expression. In the case of PPAR-g2, it was reported that its expression is regulated by DNA methylation in its promoter region (31) . We therefore tested whether Plnc1 influenced DNA methylation of the PPAR-g2 promoter. Using loss-of-function and gain-of-function strategies, we demonstrated that Plnc1 down-regulated the methylation level of the PPAR-g2 promoter. Nonmethylated PPAR-g2 promoter had higher transcriptional activity than methylated promoter in cells cultured with either basal medium or adipogenic medium. As expected, adipogenic treatment potentiated the promoter activity. Plnc1 further increased PPAR-g2 promoter activity in either nonmethylated or methylated status. Further investigation revealed that Plnc1 could reduce DNA methylation levels on the methylated promoter of PPAR-g2. We conclude that Plnc1 enhances the promoter activity of PPAR-g2 through attenuating the methylation status of the promoter, thereby increasing PPAR-g2 transcripts and promoting adipogenesis.
Plnc1 also increased the transcriptional activity of the nonmethylated PPAR-g2 promoter in the presence of adipogenic medium. There are some lncRNAs serving as modular scaffolds or tether protein factors to form chromatin-modifying complexes that regulate cell differentiation (39, 45, 46) . These suggest there might exist other mechanisms for the regulation of PPAR-g2 by Plnc1. Because the findings in this study are mainly based on in vitro experiments, in vivo experiments, especially with genetic knockout or knockin mice, may be needed to further clarify the requirement of Plnc1 for adipogenesis and its correlation to obesity.
In summary, we have identified an uncharacterized intronic lncRNA, Plnc1 which is highly expressed in adipose tissue. It acts as a critical positive regulator in adipogenic differentiation. This conclusion is based upon its function to enhance the promoter activity of PPAR-g2 through attenuating the methylation status of the promoter, thereby increasing PPAR-g2 transcripts. The current study also suggests that Plnc1 may be a potential target for new therapies aimed at controlling metabolic disorders caused by adipogenic dysregulation, such as obesity.
